Literature DB >> 1157014

Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile.

G B Bulkley, M H Cohen, P M Banks, D H Char, A S Ketcham.   

Abstract

A case of a 58-year-old woman with viscerally metastatic malignant melanoma is presented 12 years after spontaneous and complete regression of disease. Diagnosis of primary and metastatic lesions was confirmed by review of tissue sections. The presence and subsequent absence of visceral metastases were documented by open liver biopsies. Sections of metastatic lesions revealed extensive necrosis of tumor and infiltration of lymphocytes and plasma cells. Skin testing showed a strongly positive delayed hypersensitivity response to dinitrochlorobenzene (DNCB), to a standard battery of bacterial and fungal antigens, and to two of four preparations of allogeneic melanoma antigens. Values for cell- and serum-mediated cytotoxicity against melanoma cells and the response of the patient's lymphocytes to phytohemagglutinin were slightly above the normal range. A review of the literature reveals 13 other cases of long-term spontaneous regression of melanoma. None of these, however, had biopsy evidence of visceral disease. In each of the 13 cases, regression was associated with an event that might be inferred to have altered the patient's hormonal or immune status. This patient also provides evidence of a complete, spontaneous, and long-term remission of metastatic disease associated with the spontaneous development of host immunity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1157014     DOI: 10.1002/1097-0142(197508)36:2<485::aid-cncr2820360227>3.0.co;2-m

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Spontaneous regression of metastatic visceral malignant melanoma.

Authors:  K R Haight; D V Shapira; G W Cates
Journal:  Can Fam Physician       Date:  1984-06       Impact factor: 3.275

2.  The biologic importance of tumor-infiltrating lymphocytes.

Authors:  F Stephen Hodi; Glenn Dranoff
Journal:  J Cutan Pathol       Date:  2010-04       Impact factor: 1.587

3.  Natural history of cutaneous malignant melanoma.

Authors:  H A Briele; T K Das Gupta
Journal:  World J Surg       Date:  1979-07-30       Impact factor: 3.352

4.  Staging laparotomy in the treatment of metastatic melanoma of the lower extremities.

Authors:  M H Cohen; L Schour; E L Felix; A D Bernstein; P B Chretien; S A Rosenberg; A S Ketcham
Journal:  Ann Surg       Date:  1975-12       Impact factor: 12.969

5.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

6.  Human malignant melanoma antigenic properties of phenol water extracts.

Authors:  L Suter; H Tilkorn; P M Kövary
Journal:  Arch Dermatol Res       Date:  1979-02-23       Impact factor: 3.017

7.  Balloon cell malignant melanoma of the choroid: ultrastructural studies.

Authors:  M K Khalil
Journal:  Br J Ophthalmol       Date:  1983-09       Impact factor: 4.638

8.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.

Authors:  R Soiffer; T Lynch; M Mihm; K Jung; C Rhuda; J C Schmollinger; F S Hodi; L Liebster; P Lam; S Mentzer; S Singer; K K Tanabe; A B Cosimi; R Duda; A Sober; A Bhan; J Daley; D Neuberg; G Parry; J Rokovich; L Richards; J Drayer; A Berns; S Clift; L K Cohen; R C Mulligan; G Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

9.  Clinical aspects of unknown primary melanoma.

Authors:  A E Giuliano; H S Moseley; D L Morton
Journal:  Ann Surg       Date:  1980-01       Impact factor: 12.969

10.  Epidemiologic clues to the cause of melanoma.

Authors:  W E Morton; G F Starr
Journal:  West J Med       Date:  1979-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.